The effects of protein synthesis inhibitor on the expression and re-consolidation on pentylenetetrazol kindler seizuresp.322

• Autorzy: Maciejak P. , Szyndler J. , Turzynska D. , Sobolewska A. , Taracha E. , Skorzewska A. , Lehner M. , Krzascik P. , Hamed A. , Bidzinski A. , Plaznik A.
• Języki publikacji: EN

Abstrakty

EN

In the present study the effects of a protein synthesis inhibitor, cycloheximide (125 μg, i.c.v.), on the expression and reconsolidation of pentylenetetrazol-induced kindled seizures, were studied in rats. Cycloheximide given repeatedly (every second day) to fully kindled rats, immediately after 4 consecutive sessions of PTZ-seizures, did not modify the strength of subsequent fi ts of convulsions. On the other hand, the protein synthesis inhibitor signifi cantly attenuated the strength of convulsions when the drug was administered 1 h before the PTZ injection, every second day for 5 consecutive experimental sessions. However, when cycloheximide was omitted in a consecutive session, PTZ induced a fully developed fi t of tonicclonic convulsions, indicating that cycloheximide-induced changes in seizure intensity were transitory, not related to a stable modifi cation in the function of neuronal circuits responsible for kindling seizures. The present fi ndings suggest that the mechanisms underlying epileptogenesis are very resistant to modifi cation, and as such, are not the subject to permanent changes even under the infl uence of protein synthesis inhibition. One possible reason may be the depth and multiplicity of changes induced by seizures (i.e. alterations in enzymes, receptors, structural proteins, growth factors, etc.), that may cause permanent biochemical and morphological alterations in the brain that give rise to the kindled seizures.

• Wydawca: -
• Czasopismo: Acta Neurobiologiae Experimentalis
• Rocznik: 2009
• Tom: 69
• Numer: 3
• Opis fizyczny: p.332

Twórcy

autor

Maciejak P.

• Department of Neurochemistry, Institute of Psychiatry and Neurology, Warsaw, Poland
• Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland

autor

Szyndler J.

• Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland

autor

Turzynska D.

• Department of Neurochemistry, Institute of Psychiatry and Neurology, Warsaw, Poland

autor

Sobolewska A.

• Department of Neurochemistry, Institute of Psychiatry and Neurology, Warsaw, Poland

autor

Taracha E.

• Department of Neurochemistry, Institute of Psychiatry and Neurology, Warsaw, Poland

autor

Skorzewska A.

• Department of Neurochemistry, Institute of Psychiatry and Neurology, Warsaw, Poland

autor

Lehner M.

• Department of Neurochemistry, Institute of Psychiatry and Neurology, Warsaw, Poland

autor

Krzascik P.

• Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland

autor

Hamed A.

• Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland

autor

Bidzinski A.

• Department of Neurochemistry, Institute of Psychiatry and Neurology, Warsaw, Poland

autor

Plaznik A.

• Department of Neurochemistry, Institute of Psychiatry and Neurology, Warsaw, Poland
• Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland